Soumya Paul

Soumya Paul is CEO at Pentavalent Biosciences.

Articles by Soumya Paul

strigana/Stock.Adobe.com – image of magnifying class taking a close look at vials and syringes.

Platform-Specific Risk Assessment of SARS-CoV-2 Vaccines Using FMEA

ByRajika Jindani ,Smritie Sheth,Soumya Paul,Anurag S. Rathore,Narendra Chirmule

February 2nd 2021

Amid the rush for a SARS-CoV-2 vaccine to deal with the COVID-19 pandemic, a robust risk assessment must be conducted, and mitigation strategies applied.

Soumya Paul

Articles by Soumya Paul

Platform-Specific Risk Assessment of SARS-CoV-2 Vaccines Using FMEA

Latest Updated Articles

Trending on BioPharm International

Therapeutic Nucleic Acids: Advanced Solutions for Downstream Processing & Analysis

Rentschler’s Time Capsule and How it Symbolizes European Biotech Progress

Analytics, Automation, and Quality Driving the Next Era of Drug Development